Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06350825 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients

Name: Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients — clinical trial record (NCT06350825)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorThe First Affiliated Hospital with Nanjing Medical University

Started2016-01-01

View on ClinicalTrials.gov ↗

The First Affiliated Hospital with Nanjing Medical University

275 trials monitored

See 6 trials at risk

Prostate Cancer

2,471 trials monitored

See 156 trials at risk

To evaluate: The radiographic progression-free survival (rPFS) of metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with androgen deprivation therapy (ADT) + second-generation antiandrogens±chemotherapy combined with cytoreductive prostatectomy (CRP)

Trial Details

NCT Number	NCT06350825
Lead Sponsor	The First Affiliated Hospital with Nanjing Medical University
Conditions	Metastatic Prostate Cancer, Therapy, Directly Observed
Enrollment	200 participants
Start Date	2016-01-01
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-04-05